UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 646-651

  Hajdinjak, Tine ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Bladder neoplasms; Cytodiagnosis; Fluorescence; in Situ hybridization; Sensitivity; Specificity; Urine

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER PROGRAM; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; URINE CYTOLOGY; UROGENITAL TRACT CANCER; UROTHELIUM; UROTHELIUM CANCER;

CYTODIAGNOSIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 55249098918     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.06.002     Document Type: Article

References (33)

1. Jones J.S. DNA-based molecular cytology for bladder cancer surveillance. Urology 67 (2006) 35-45
2. Phillips J.L., and Richardson I.C. Aneuploidy in bladder cancers: The utility of fluorescent in situ hybridization in clinical practice. BJU Int 98 (2006) 33-37
3. Hajdinjak T., Kokalj-Vokač N., Marin-Aguilera M., Mengual L., Ribal M.J., et al. Utility of fluorescence in situ hybridization as a noninvasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 52 (2007) 288-289
4. Zamora J., Abraira V., Muriel A., et al. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol 6 (2006) 31
5. Mian C., Lodde M., Comploj E., et al. Multiprobe fluorescence in situ hybridization: Prognostic perspectives in superficial bladder cancer. J Clin Pathol 59 (2006) 984-987
6. Zellweger T., Benz G., Cathomas G., et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 119 (2006) 1660-1665
7. Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagnost 2 (2000) 116-123
8. Halling K.C., King W., Sokolova I.A., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768-1775
9. Halling K.C., King W., Sokolova I.A., et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167 (2002) 2001-2006
10. Dalquen P., Kleiber B., Grilli B., et al. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer 96 (2002) 374-379
11. Bubendorf L., Grilli B., Sauter G., et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116 (2001) 79-86
12. Degtyar P., Neulander E., Zirkin H., et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology 63 (2004) 398-401
13. Constantinou M., Binka-Kowalska A., Borkowska E., et al. Application of multiplex FISH, CGH, and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens. J Appl Genet 47 (2006) 273-275
14. Marin-Aguilera M., Mengual L., Ribal M.J., et al. Utility of fluorescence in situ hybridization as a noninvasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 51 (2007) 409-415
15. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
16. Placer J., Espinet B., Salido M., et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42 (2002) 547-552
17. Veeramachaneni R., Nordberg M.L., Shi R., et al. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagnost Cytopathol 28 (2003) 301-307
18. Friedrich M.G., Toma M.I., Hellstern A., et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 92 (2003) 911-914
19. Mian C., Lodde M., Comploj E., et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology 14 (2003) 338-342
20. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
21. Varella-Garcia M., Akduman B., Sunpaweravong P., et al. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 22 (2004) 16-19
22. Laudadio J., Keane T.E., Reeves H.M., et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. BJU Int 96 (2005) 1280-1285
23. Kang J.U., Koo S.H., Jeong T.E., et al. Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet 164 (2006) 32-38
24. Sarosdy M.F., Kahn P.R., Ziffer M.D., et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176 (2006) 44-47
25. Junker K., Fritsch T., Hartmann A., et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 114 (2006) 279-283
26. Moonen P.M., Merkx G.F., Peelen P., et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51 (2007) 1275-1280
27. Marin-Aguilera M., Mengual L., Ribal M.J., et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet 173 (2007) 131-135
28. Nakama H., Zhang B., and Fattah A.S. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer 36 (2000) 647-650
29. Deeks J.J., and Altman D.G. Diagnostic tests 4: Likelihood ratios. BMJ 329 (2004) 168-169
30. Jaeschke R., Guyatt G.H., and Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271 (1994) 703-707
31. Pewsner D., Battaglia M., Minder C., et al. Ruling a diagnosis in or out with "SpPIn" and "SnNOut": A note of caution. BMJ 329 (2004) 209-213
32. Rodgers M., Nixon J., Hempel S., et al. Diagnostic tests and algorithms used in the investigation of hematuria: Systematic reviews and economic evaluation. Health Technol Assess 10 (2006) iii-259
33. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-475